Silexion Therapeutics (SLXN) Change in Accured Expenses (2023 - 2026)

Silexion Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at -$319000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1672.22% year-over-year to -$319000.0; the TTM figure through Mar 2026 stood at -$112000.0 (up 58.52% YoY), while the FY2025 annual figure was $237000.0, up 112.48% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$319000.0, down from $158000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $509000.0 in Q4 2023, with the low at -$1.0 million in Q4 2024.
• The 4-year median for Change in Accured Expenses is $7500.0 (2023), against an average of -$15083.3.
• The sharpest annual moves came in 2024 and 2026: Change in Accured Expenses jumped 1221.21% in 2024, then slumped 1672.22% in 2026.
• Silexion Therapeutics' Change in Accured Expenses stood at $509000.0 in 2023, then sank by 299.41% to -$1.0 million in 2024, then surged by 115.57% to $158000.0 in 2025, then plunged by 301.9% to -$319000.0 in 2026.
• Business Quant data shows SLXN's Change in Accured Expenses at -$319000.0 in Q1 2026, $158000.0 in Q4 2025, and $88000.0 in Q3 2025.